MIMEDX GROUP, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M |
| Gross profit | $345.6M | $288.8M | $266.8M | $219.5M | $202.4M |
| Operating income | $63.9M | $58.9M | $37.1M | -$14.7M | -$7.1M |
| Cost of revenue | $73.0M | $60.1M | $54.6M | $48.3M | $39.6M |
| Cash from operations | $74.0M | $66.2M | $26.8M | -$17.9M | -$2.0M |
| Capital expenditure | $0 | $0 | $2.0M | $1.5M | $3.2M |
| Free cash flow | $74.0M | $66.2M | $24.8M | -$19.4M | -$5.2M |
| Share repurchases | $0 | $0 | $9.5M | $0 | $0 |
| Impairments | — | — | $0 | $0 | $0 |
| Total assets | $342.7M | $263.9M | $239.0M | $171.4M | $187.9M |
| Total liabilities | $86.1M | $70.8M | $96.3M | $96.9M | $95.4M |
Shares outstanding 148.9M · Free float 68.6%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.